1. Introduction {#sec1-ijerph-17-01597}
===============

Diabetes mellitus is well recognized as a global public health crisis. It is a chronic metabolic disorder characterized by elevated blood glucose levels due to the body's impaired insulin secretion and/or insulin resistance \[[@B1-ijerph-17-01597]\]. Persistent diabetes devastates vascular and nerve systems, causing many severe life-threatening complications (e.g., cardiovascular diseases, neuropathy, diabetic foot complications, diabetic retinopathies, or renal failure) and increasing the risk of hospitalization and mortality \[[@B2-ijerph-17-01597],[@B3-ijerph-17-01597],[@B4-ijerph-17-01597]\]. This disease has now been among the leading causes of disease burden worldwide \[[@B5-ijerph-17-01597]\]. According to global estimates, in 2017, over 451 million people were reported to be living with diabetes, with more than 5 million diabetes-related deaths \[[@B1-ijerph-17-01597]\].

Like other chronic diseases, diabetes cannot be completely cured \[[@B6-ijerph-17-01597]\]. Therefore, ensuring that people living with diabetes have a good quality of life (QOL) and can function adequately has become the ultimate goal of diabetic care \[[@B7-ijerph-17-01597]\]. Research increasingly looks to QOL as a favorable outcome of interventions focused on diabetes \[[@B2-ijerph-17-01597],[@B6-ijerph-17-01597]\]. QOL is a multidimensional concept that does not have a unified definition \[[@B8-ijerph-17-01597],[@B9-ijerph-17-01597],[@B10-ijerph-17-01597],[@B11-ijerph-17-01597]\]. The World Health Organization defines QOL as "an individual's perceptions of their position in life, in the context of the culture and value systems in which they live, and in relation to their goals, expectations, standards, and concerns" \[[@B11-ijerph-17-01597]\]. When two treatments have similar clinical outcomes, measuring QOL can reflect patients' different experiences or perceptions of treatments and symptoms, helping clinicians to identify which intervention's benefits outweigh its drawbacks \[[@B12-ijerph-17-01597]\]. In the case of diabetes, evaluating QOL is critically important as its enhancement is associated with good self-care management, including adherence to prescribed medication and suggested lifestyle modifications, which are significant protective factors for diabetes care \[[@B2-ijerph-17-01597],[@B6-ijerph-17-01597],[@B13-ijerph-17-01597],[@B14-ijerph-17-01597]\].

A growing body of literature (including trials, systematic reviews, and meta-analyses) examines the effectiveness of various approaches (from health education to behavioral modification, pharmacotherapy, and surgery \[[@B12-ijerph-17-01597],[@B15-ijerph-17-01597],[@B16-ijerph-17-01597],[@B17-ijerph-17-01597],[@B18-ijerph-17-01597]\]) in enhancing treatment outcomes and QOL among people with diabetes. However, few publications feature updated quantitative data (i.e, bibliometric or scientometric analysis) focusing on interventions aimed at improving QOL in people living with diabetes. Recently, most of the published bibliometric studies have concentrated on diabetes in general \[[@B19-ijerph-17-01597],[@B20-ijerph-17-01597],[@B21-ijerph-17-01597]\], diabetic complications \[[@B22-ijerph-17-01597]\] or comorbidities \[[@B23-ijerph-17-01597]\], and the use of specific therapy in diabetes treatment \[[@B24-ijerph-17-01597]\]. Looking at these offers a comprehensive picture of the current approaches utilized for improving QOL, the status of international collaboration, and the gap between high- and low-income nations, which is vital in developing a roadmap for a global research agenda that will help optimize diabetes treatment outcomes. The aim of this study is thus to assess the outcomes of recent interventions to improve QOL of people with diabetes.

2. Materials and Methods {#sec2-ijerph-17-01597}
========================

2.1. Searching Strategy {#sec2dot1-ijerph-17-01597}
-----------------------

We performed a combined bibliometric and content analysis of publications covering the interventions to improve QOL among people with diabetes. The Web of Science (WOS) Core Collection was selected for the retrieval of data from 1900 to 31 December, 2018. The reasons for selecting the WOS include the availability of necessary information for analyzing contents of papers such as names and addresses of authors, titles/abstracts of articles, keywords, total citations and downloads, and research area coverage, which is far more than other accessible databases. Moreover, this database has a high citation report coverage and supports various analysis measures that facilitate bibliometric analysis of the existing literature \[[@B25-ijerph-17-01597],[@B26-ijerph-17-01597]\].

Articles were included if they (1) involved interventions (randomized controlled trials \[RCTs\], pre-post or quasi-experiments); (2) focused on people with diabetes as the targeted population; (3) had QOL or health-related QOL as primary or secondary outcomes; (4) were original articles; (5) were published in English scientific journals indexed in the WOS; and (6) had comprehensive information on the authors.

We excluded gray literature (e.g., reports, dissertations, theses, letters, news, etc.), book and book chapters, and conference abstracts/proceedings because some of these might have been published as scientific papers in peer-reviewed journals which could cause duplications. Papers without author information were also excluded because they could not be used to analyze the affiliation and collaboration networks across countries. Additionally, papers about narrative reviews/systematic reviews/meta-analysis studies were excluded because they were not original studies, which might not reflect the tendency of research development. Study protocols of interventions or papers reporting only baseline characteristics were not eligible because they did not assess the effect of specific interventions on the QOL.

To identify relevant articles, we performed the search strategy as follows:-First, we produced a QOL dataset by employing topic search terms such as "quality of life" and "well-being" on the WOS. Among 441,617 records after searching, we excluded 114,212 documents (including: 4364 papers that were published in 2019; 25,543 documents that were non-English articles; 84,083 documents that were not articles/reviews; and 222 documents that had insufficient author information). A total of 327,405 quality of life-related papers were used for the next step.-Second, we filtered the papers regarding interventions in diabetes populations by using a set of title/abstract terms related to "diabetes" (AND "intervention" OR "trial") and saved it as the final dataset. A total of 323,079 papers were excluded, resulting in 4326 papers that were included in the next phase.-Finally, we screened 4326 papers by reading their titles and abstracts and excluded 3626 papers that were not eligible according to the inclusion and exclusion criteria.

Full records of articles were exported and downloaded independently by two members in the research team. The third researcher performed a cross-check between two datasets to ensure their consistency.

2.2. Data Analysis {#sec2dot2-ijerph-17-01597}
------------------

STATA version 15.0 (STATA Corp., TX, USA) was utilized for data analysis. We performed a descriptive analysis using the following indicators: publication year, the number of papers per country/per year, total citations up to 2018, mean citation rate per year, total usage in the last six months/five years, and mean use rate in the last six months/five years. The VOSviewer (version 1.6.8, Center for Science and Technology, Leiden University, the Netherlands) was employed to illustrate the co-occurrence of the most frequent terms in titles and abstracts. Country collaboration networks were illustrated by using the Circos platform \[[@B27-ijerph-17-01597]\]. As for content analysis, we analyzed the hierarchical clustering of major research disciplines in the interventions and visualized it in a Dendrogram. Thematic analysis was performed using the Latent Dirichlet Allocation (LDA) technique, which supports classified papers in ten major themes/topics \[[@B18-ijerph-17-01597],[@B28-ijerph-17-01597],[@B29-ijerph-17-01597],[@B30-ijerph-17-01597],[@B31-ijerph-17-01597]\]. Titles and abstracts of papers in every topic/theme were then reviewed by two researchers. Any disagreements were addressed by discussing it with a senior researcher. We then calculated the number of papers per topic and determined any change in research interests by ranking the total number of publications per topic in the past five years (from 2013--2018).

3. Results {#sec3-ijerph-17-01597}
==========

[Figure 1](#ijerph-17-01597-f001){ref-type="fig"} illustrates the searching process. Among the 327,405 papers on QOL, 700 papers on interventions to improve QOL of people with diabetes were selected as eligible.

[Table 1](#ijerph-17-01597-t001){ref-type="table"} shows that in the period 1990--2018, there were a total of 700 papers published about interventions to improve the QOL among people with diabetes. From the first paper counted in 1990, the volume of annual articles increased significantly over time to reach a peak of 67 papers in 2015, before falling to 63 papers by the end of 2018. Papers published in 2005 and 1998 had the highest mean citation rate per year (9.7 and 9.0, respectively). Articles published in 2015 and 2005 had the highest total usage (i.e., the total number of downloads) and mean use rate in the last five years, respectively. In the last six months, the total usage and the mean use rate of papers published in 2018 were higher than those published in other years.

Overall, 700 papers were published by authors in 61 countries. The United States (U.S.) and the United Kingdom (U.K.) contributed the most publications (322 and 160 papers, respectively), followed by Germany (101 papers), Australia (87 papers), and the Netherlands (85 papers). Only China was the only middle-income country in the top ten nations with the greatest number of publications, while the others were high-income nations. Meanwhile, among the top 20 countries, only China, India, Malaysia, and Iran were middle-income countries.

[Figure 2](#ijerph-17-01597-f002){ref-type="fig"} depicts networks of collaboration among the top 20 countries having the highest volume of publications. The U.K. and the U.S. had the highest amount of collaborations, with 28 and 25 countries, correspondingly. In the U.S., among 322 published papers, there were more than 610 affiliations mentioned. Approximately 80% of them were from U.S. authors (\~490 affiliations), 4% were from the U.K. (\~23 affiliations), and 2% were from Denmark (\~10 affiliations). Similarly, in the U.K., 160 papers were products of authors from 290 affiliations (or organizations), with \~58% from the U.K., 8% from the U.S. and 6% from Australia. These countries were followed by Germany (22 countries), Denmark (18 countries), and the Netherlands (18 countries).

To illustrate the scope of the selected studies, we performed a content analysis to evaluate the co-occurrence of the most frequent terms in the abstracts and titles. [Figure 3](#ijerph-17-01597-f003){ref-type="fig"} shows four major clusters emerging from the 271 most common keywords with a co-occurrence rate of at least 15: (1) the yellow cluster refers to clinical trials to test the efficacy and safety of drugs, as well as to control pain and overweight/obesity among people with diabetes (e.g., placebo, efficacy, safety, dose, pain, body weight, obesity, weight loss); (2) the blue cluster indicates trials focusing on diabetes prevention such as lifestyle- or behavior-related interventions (e.g., physical activity, exercise training, diet, etc.); (3) the green cluster covers the interventions using insulin-related therapies to control blood glucose level, particularly among patients with type 1 diabetes (e.g., insulin treatment, insulin glargine, etc.); and (4) the red cluster refers to interventions in the community to promote self-care capability (e.g., self-care, practice, self-efficacy, caregivers, etc.), as well as reduce the risk of psychological problems (e.g., depression or distress) among people with diabetes, especially in adolescents and children (e.g., adolescent, child, parent).

The top 10 clinical trials having the highest number of citations are presented in [Table 2](#ijerph-17-01597-t002){ref-type="table"}. All of them were RCTs, which focused mainly on the effectiveness of different medications, surgery, or behavioral therapies in controlling blood glucose; reducing the negative effects of diabetic complications (such as diabetic neuropathy, obesity, limb ischemia, or perinatal complications); and improving QOL in people with diabetes, especially pregnant women, children, and adolescents. Among the top three papers, the first paper, by Crowther et al., titled "Effect of treatment of gestational diabetes mellitus on pregnancy outcomes," published in 2005 in the *New England Journal of Medicine,* had the highest number of citations and evaluated the efficacy of dietary advice, blood glucose monitoring, and insulin therapy (by comparing the intervention group to a control group receiving only routine care) in treating gestational diabetes in pregnant women to prevent perinatal complications \[[@B32-ijerph-17-01597]\]. By using the Short-form 36 (SF-36) instrument, the results of this study showed a significant increase in QOL among participants \[[@B32-ijerph-17-01597]\]. The second paper, titled "Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus---A randomized controlled trial," also used SF-36 and showed that gabapentin use significantly improved the QOL of patients with diabetic neuropathy compared to the placebo group \[[@B33-ijerph-17-01597]\]. The SF-36 was also used in the third-most cited paper, entitled "Bariatric Surgery versus Intensive Medical Therapy for Diabetes-3-Year Outcomes" \[[@B34-ijerph-17-01597]\]. The authors of this study indicated that bariatric surgery significantly enhanced health-related QOL among obese patients with type 2 diabetes compared to those receiving intensive medical therapy only \[[@B34-ijerph-17-01597]\].

[Figure 4](#ijerph-17-01597-f004){ref-type="fig"} presents the hierarchical clustering of major research disciplines in interventions aiming to improve the QOL of people with type 2 diabetes. The horizontal axis reflects the dissimilarity between clusters, while the vertical axis reveals disciplines of pooled papers. This figure shows that interventions were separated into five major clusters. In the first cluster, the "Pediatrics" grouping is connected to "Endocrinology and Metabolism," suggesting that the majority of interventions for children with diabetes and adolescents were concentrated on using medications to enhance metabolic pathways such as insulin infusion or an insulin pump.

Meanwhile, the second cluster indicated clinical and lifestyle interventions to improve QOL in people with diabetes in general or with multiple comorbidities (such as cardiac disease and mental problems). For example, the "Pharmacology and Pharmacy" grouping was joined with "Medicine, Research and Experiment," which indicated that interventions using a pharmacological approach such as fenofibrate, ranolazine, or other drugs in glycemic control, reduced the damage done by diabetes and its complications and improved QOL. In addition, the "Sport Sciences" discipline was combined with the "Geriatrics and Gerontology" disciplines, showing that the common intervention approaches in older people with diabetes were facilitating physical activity. Similarly, for people with diabetes suffering cardiac illnesses ("Cardiac and Cardiovascular System"), "Surgery" and "Nutrition and Dietetics" were the two most common interventions.

The third cluster reveals clinical interventions to improve the QOL of people with diabetes in primary care settings. These included home- or community-based interventions.

Meanwhile, the fourth cluster indicated clinical interventions to enhance the QOL of people with diabetes suffering from neurological pain.

Finally, the fifth cluster showed public health, health service, health policy, and medical-information-technology-related interventions aiming to improve the QOL of people with diabetes. Notably, this cluster is not close to other groupings in the figure.

By using LDA, we categorized the selected interventions under ten major topic headings. The three topics with the highest number of publications included: (1) community-, family-, and eHealth-based interventions to improve self-management and self-efficacy; (2) lifestyle (e.g., physical activity and dietary) interventions in people with diabetes; (3) interventions focused on comorbidities in people with diabetes ([Table 3](#ijerph-17-01597-t003){ref-type="table"}). The first topic was investigated in 187 papers, accounting for 26.7% of total papers. Meanwhile, the second and third topics accounted for 17.7% and 15.3%, respectively.

[Figure 5](#ijerph-17-01597-f005){ref-type="fig"} shows the correlation of publications to the ten topics. Recently, topics 1 and 2 received the greatest attention, with the largest number of publications every year in the three years 2015--2018. In the same period, the number of publications on topics 3 and 4 also increased, while the volume of publications on other topics decreased.

4. Discussion {#sec4-ijerph-17-01597}
=============

Our study presents an overview of global research on interventions supporting QOL among people with diabetes during the period 1990--2018. The findings of this study indicated a general increase in the overall number of articles about this issue over time, and a significant disparity in the contributing countries based on income level. Community- and family-based interventions, including those focused on lifestyle and those utilizing digital technologies, were common approaches. Interventions that addressed comorbidities in people with diabetes also increased over the period. Our findings emphasize the necessity of translating the evidence from clinical interventions to community interventions. In addition, they underline the importance of developing collaborative research between high-income countries (HICs) and low- and middle-income countries (LMICs). It is particularly true since LMICs are predicted to experience a substantially greater diabetes burden in the coming years \[[@B41-ijerph-17-01597]\].

Diabetes is a chronic condition and requires good self-management and long-term metabolic control for patients' QOL to improve \[[@B42-ijerph-17-01597]\]. Our analysis confirmed the findings of previous reviews \[[@B43-ijerph-17-01597]\] regarding approaches seen to increase the QOL of people with diabetes, including pharmacotherapy, surgery, and educational or lifestyle interventions to control blood glucose or diabetic complications, in both online (e.g., Internet or telephone) and offline settings (e.g., hospital, community, family, or school). Amid the increase in the diabetes burden as well as its pervasiveness in communities around the world, there is no doubt that community-, family-, or even online-based interventions are important to consider. This is confirmed by the high and growing number of publications on them, relative to other topics in the healthcare sector. We found that most studies focused on improving the self-management and self-efficacy of patients with diabetes, helping them monitor and control their blood glucose levels, as well as prevent the onset of diabetic complications \[[@B44-ijerph-17-01597]\]. This topic is followed by the application of lifestyle interventions (including diet with active physical activity), which plays a major role in enhancing diabetes outcomes and improving QOL. An earlier review of this type of intervention showed that it was more effective than pharmacotherapy in alleviating diabetic symptoms and complications, as well as in preventing the onset of diabetes \[[@B45-ijerph-17-01597]\]. The remaining topics included interventions to control and treat comorbidities and other complications such as neuropathic pain, mental disorders, cardiac diseases, and functional impairment such as foot ulcers or sexual disfunction. It has been confirmed in prior reviews that these problems significantly affect the QOL of people with diabetes \[[@B42-ijerph-17-01597],[@B46-ijerph-17-01597]\]; therefore, medical approaches to solving these issues are critical to improving QOL not only in hospital settings but also in primary care and community settings.

Notably, this study revealed a skewed geographical distribution of the selected publications toward HICs such as the United States, England, Germany, Australia, and the Netherlands. China was the only middle-income country among the top 10 active nations. However, it should be noted that the burden of diabetes has been much greater for LMICs than for HICs. In 2016, a global report showed that among the 425 million people living with diabetes, approximately 80% of them resided in LMICs, and this figure is expected to increase significantly in the coming decades \[[@B1-ijerph-17-01597]\]. This disparity was in line with a previous bibliometric study about diabetes, depression, and suicide, though these same countries had the highest volume of publications on this topic \[[@B23-ijerph-17-01597]\]. Other scientometric studies also underlined the insufficient contribution of LMICs to research, which does not help diminish the diabetes burden in these nations \[[@B19-ijerph-17-01597],[@B20-ijerph-17-01597],[@B47-ijerph-17-01597],[@B48-ijerph-17-01597]\]. The concept of QOL refers to the individual's perception of physical, psychological, and social conditions in a specific context and culture \[[@B11-ijerph-17-01597]\]. Thus, more contextualized evidence about the effects of interventions on the QOL of people with diabetes in LMICs is required to increase the applicability of these interventions. Insufficient evidence from LMICs might be due to a lack of funding sources, human resources, and infrastructure for research institutions \[[@B47-ijerph-17-01597],[@B48-ijerph-17-01597],[@B49-ijerph-17-01597]\]. This gap may not be fulfilled in the short term, but these countries might benefit from using evidence from neighboring nations having similar cultural, socioeconomic, and value systems. Regional collaborative networks may be developed such that LMICs with high research productivity (such as China and India) play a central role, with support from HICs. Such initiatives could strengthen the research capacity of member countries as well as increase the quality of evidence, which would serve as a foundation for further strategies to increase QOL of people with diabetes.

This study has several limitations. First, our sample was limited to English-language publications indexed in the WOS database. This may not reflect the development of publications on interventions improving QOL among people with diabetes in countries where English is not a native language. Therefore, publications from these countries, many of them LMICs, might be underestimated. Additionally, we did not use the full text of publications for our content analysis. That said, we analyzed various levels of data, including keywords, the text of the title and abstract, and research discipline categories, and also employed advanced analytical methods such as LDA \[[@B50-ijerph-17-01597]\].

5. Conclusions {#sec5-ijerph-17-01597}
==============

Global research on interventions to improve the QOL of people with diabetes gradually increased in recent decades, with major contributions from HICs. Community- and family-based interventions, including those focused on lifestyle and utilizing digital technologies, have been common. Interventions to address comorbidities in people with diabetes have also been on the rise. More contextualized interventions in LMICs, as well as regional initiatives to support LMICs in translating worldwide evidence, should be facilitated to alleviate the diabetes burden in these countries.
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ijerph-17-01597-t001_Table 1

###### 

General characteristics of publications analyzed.

  Year Published   Total Number of Papers   Total Citations   Mean Cite Rate Per Year   Total Usage Last 6 Months ^1^   Total Usage Last 5 Years ^2^   Mean Use Rate Last 6 Months   Mean Use Rate Last 5 Years
  ---------------- ------------------------ ----------------- ------------------------- ------------------------------- ------------------------------ ----------------------------- ----------------------------
  2018             63                       158               2.5                       218                             405                            3.5                           1.3
  2017             56                       556               5.0                       95                              494                            1.7                           1.8
  2016             57                       455               2.7                       51                              601                            0.9                           2.1
  2015             67                       1009              3.8                       77                              1,135                          1.1                           3.4
  2014             59                       1845              6.3                       67                              927                            1.1                           3.1
  2013             46                       1205              4.4                       25                              808                            0.5                           3.5
  2012             53                       1342              3.6                       28                              871                            0.5                           3.3
  2011             41                       1127              3.4                       16                              501                            0.4                           2.4
  2010             33                       1020              3.4                       24                              380                            0.7                           2.2
  2009             34                       1590              4.7                       23                              370                            0.7                           2.2
  2008             24                       1372              5.2                       10                              297                            0.4                           2.5
  2007             27                       1244              3.8                       18                              308                            0.7                           2.3
  2006             20                       1038              4.0                       8                               156                            0.4                           1.6
  2005             18                       2438              9.7                       18                              335                            1.0                           3.7
  2004             17                       930               3.6                       3                               94                             0.2                           1.1
  2003             9                        870               6.0                       3                               79                             0.3                           1.8
  2002             13                       1233              5.6                       1                               79                             0.1                           1.2
  2001             12                       978               4.5                       0                               65                             0.0                           1.1
  2000             13                       1355              5.5                       8                               140                            0.6                           2.2
  1999             3                        202               3.4                       1                               9                              0.3                           0.6
  1998             12                       2265              9.0                       1                               98                             0.1                           1.6
  1997             4                        208               2.4                       2                               14                             0.5                           0.7
  1996             8                        1177              6.4                       4                               60                             0.5                           1.5
  1995             2                        202               4.2                       2                               13                             1.0                           1.3
  1994             3                        220               2.9                       2                               10                             0.7                           0.7
  1993             2                        13                0.3                       0                               0                              0.0                           0.0
  1992             2                        171               3.2                       0                               12                             0.0                           1.2
  1990             1                        37                1.3                       0                               0                              0.0                           0.0

^1^ Total usage: Total number of downloads. ^2^ Use rate: Total number of downloads/total number of papers.

ijerph-17-01597-t002_Table 2

###### 

Top 10 most cited clinical trials.

  Title                                                                                                                                                                                                                             Journal                                       Total Citations   Publication Year   Cite Rate   Study Design   Type of Diabetes                Type of Interventions                                           QOL Tool
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------- ----------------- ------------------ ----------- -------------- ------------------------------- --------------------------------------------------------------- -------------
  Effect of treatment of gestational diabetes mellitus on pregnancy outcomes \[[@B32-ijerph-17-01597]\]                                                                                                                             New England Journal of Medicine               1,516             2005               108.3       RCT            gestational diabetes mellitus   dietary advice, blood glucose monitoring, and insulin therapy   SF-36
  Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus -- A randomized controlled trial \[[@B33-ijerph-17-01597]\]                                                                     Journal of the American Medical Association   981               1998               46.7        RCT            Type 1 and type 2               Gabapentin                                                      SF-36
  Bariatric surgery versus intensive medical therapy for diabetes -- 3-year outcomes \[[@B34-ijerph-17-01597]\]                                                                                                                     New England Journal of Medicine               798               2014               159.6       RCT            Type 2                          Bariatric Surgery, Intensive Medical Therapy                    RAND-36
  Does increased access to primary care reduce hospital readmissions?                                                                                                                                                               New England Journal of Medicine               504               1996               21.9        RCT            General                         Access to Primary Care                                          SF-36
  Effectiveness of the diabetes education and self-management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: Cluster randomized controlled trial \[[@B35-ijerph-17-01597]\]   British Medical Journal                       356               2008               32.4        RCT            Type 2                          Group education programme                                       WHOQOL-BREF
  Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy \[[@B36-ijerph-17-01597]\]                                                                                                         Neurology                                     351               1998               16.7        RCT            Type 1 and type 2               Tramadol                                                        MOS
  Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy \[[@B37-ijerph-17-01597]\]                                                                                   Pain                                          324               2003               20.3        RCT            Type 1 and type 2               Controlled-release oxycodone                                    SF-36
  Randomized placebo-controlled clinical trial of Lorcaserin for weight loss in Type 2 diabetes mellitus: The BLOOM-DM study \[[@B38-ijerph-17-01597]\]                                                                             Obesity                                       294               2012               42.0        RCT            Type 2                          Lorcaserin                                                      IWQOL-LITE
  Bariatric surgery versus intensive medical therapy for diabetes -- 5-year outcomes \[[@B39-ijerph-17-01597]\]                                                                                                                     New England Journal of Medicine               293               2017               146.5       RCT            Type 2                          Bariatric Surgery, Intensive Medical Therapy                    RAND-36
  Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5-year follow-up of an open-label, single-centre, randomized controlled trial \[[@B40-ijerph-17-01597]\]                Lancet                                        289               2015               72.3        RCT            Type 2                          Bariatric-metabolic Surgery                                     RAND-36

RCT: Randomized controlled trials, SF-36 = Short-form 36, WHOQOL-BREF = WHO Quality of Life-BREF, MOS = Medical Outcomes Studies; IWQOL-LITE = Impact of Weight on Quality of Life-LITE.

ijerph-17-01597-t003_Table 3

###### 

Ten research topics classified by Latent Dirichlet Allocation.

  Rank       Research Topics                                                                                        n     Percent
  ---------- ------------------------------------------------------------------------------------------------------ ----- ---------
  Topic 1    Community-, family-, and telehealth-based interventions to improve self-management and self-efficacy   187   26.7%
  Topic 2    Lifestyle (e.g., physical activity and dietary) interventions in people with diabetes                  124   17.7%
  Topic 3    Interventions address comorbidities in people with diabetes                                            107   15.3%
  Topic 4    Education-based interventions on different aspects of the disease                                      74    10.6%
  Topic 5    Pharmacological treatment to control blood glucose levels                                              66    9.4%
  Topic 6    Pharmacological treatment for diabetic neuropathic pain                                                52    7.4%
  Topic 7    Functional complication interventions                                                                  29    4.1%
  Topic 8    Interventions addressing mental disorders in people with diabetes                                      27    3.9%
  Topic 9    Surgery and dietary interventions to promote weight loss                                               18    2.6%
  Topic 10   Pharmacological and surgical interventions to address cardiovascular complications                     16    2.3%

[^1]: These authors contributed equally to the paper.
